MS Eugia SEZ Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: MS Eugia SEZ Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $2.2M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

MS Eugia SEZ Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $2.2M Trade | TransData Nexus

MS Eugia SEZ Private Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $2.2M Total Trade · DGFT Verified

MS Eugia SEZ Private Limited is an Indian pharmaceutical exporter with a total trade value of $2.2M across 2 products in 2 therapeutic categories. Based on 44 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Piperacillin ($1.6M), Ampicillin ($650.0K), .

MS Eugia SEZ Private Limited — Export Portfolio & Destination Treemap

MS Eugia SEZ Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is MS Eugia SEZ Private Limited? — Company Overview & Market Position

MS Eugia SEZ Private Limited, established on February 20, 2021, is a private pharmaceutical company based in Hyderabad, Telangana, India. The company operates under the Corporate Identification Number (CIN) U24299TG2021PTC148856 and is registered with the Registrar of Companies (RoC) Hyderabad. Its authorized capital is ₹360 crore, with a paid-up capital of ₹4 crore. The registered office is located at Galaxy, Floors 22-24, Plot No. 1, Survey No. 83/1, Hyderabad Knowledge City, Raidurg Panmak, Hyderabad, Telangana 500032, India.

The company specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. As of November 2025, Eugia SEZ Private Limited employs approximately 500 professionals. The company's leadership comprises directors Madan Mohan Reddy Mettu, Vijay Natarajan, Mylandlahalli Rammohan Ashwini, and Santhanam Subramanian. The Annual General Meeting (AGM) was last held on September 15, 2025, with the balance sheet filed on March 31, 2025.

What Does MS Eugia SEZ Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Piperacillin$1.6M

Product Portfolio — Top 2 by Export Value

MS Eugia SEZ Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Piperacillin	Advanced Antibiotics	$1.6M	31	1.8%	6
2	Ampicillin	Antibiotics	$650.0K	13	0.5%	14

MS Eugia SEZ Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $2.2M. The top category is Advanced Antibiotics (70.5% of portfolio), followed by Antibiotics (29.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

MS Eugia SEZ Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Eugia SEZ Private Limited operates a manufacturing facility located in the Special Economic Zone (SEZ) of Polepally, Mahabubnagar District, Telangana. The facility is situated at Plot No:S-5/B, S-6 & S-7, Survey 408-412, 418-435, 437-445, 452-459 SEZ, TSIIC, Polepally Village, Jadcherla Mandal, Mahabubnagar District, India. This strategic location within the SEZ offers advantages such as tax incentives and streamlined export procedures. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding production capacities and certifications are not publicly disclosed.

3Key Leadership

The leadership team of Eugia SEZ Private Limited includes:

Madan Mohan Reddy Mettu: Director since February 20, 2021.

Vijay Natarajan: Director since February 20, 2021.

Mylandlahalli Rammohan Ashwini: Director since May 14, 2024.

Santhanam Subramanian: Director since February 20, 2021.

Venkat Reddy Kupireddy: Company Secretary since July 8, 2022.

Vallamkondu Aravind Kumar: Chief Financial Officer (CFO) since February 21, 2024.

These individuals bring a wealth of experience to the company, contributing to its strategic direction and operational success.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does MS Eugia SEZ Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Eugia SEZ Private Limited's export activities are primarily focused on the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals for its finished pharmaceutical formulations in these markets, ensuring compliance with stringent quality and safety standards. Specific details regarding the number of Abbreviated New Drug Applications (ANDAs) filed with the U.S. FDA, European Medicines Agency (EMA) approvals, and other market access statuses are not publicly disclosed. The company's adherence to Good Manufacturing Practices (GMP) and other regulatory requirements facilitates its presence in these regulated markets.

2Emerging Markets

Eugia SEZ Private Limited has made strategic inroads into emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's products have been prequalified by the World Health Organization (WHO), enabling access to these markets and enhancing its global footprint. The WHO prequalification process ensures that Eugia's products meet international standards of quality, safety, and efficacy, thereby facilitating smoother market entry and acceptance.

3Geographic Strategy

MS Eugia SEZ Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Eugia SEZ Private Limited's manufacturing facility in Mahabubnagar District, Telangana, has been inspected by the U.S. Food and Drug Administration (FDA). The most recent inspection occurred in February 2024, resulting in the issuance of an FDA Form 483, which outlines observations made during the inspection. The company has addressed the observations raised in the Form 483, demonstrating its commitment to compliance with FDA regulations. Specific details regarding the number of Abbreviated New Drug Applications (ANDAs) filed, Drug Master File (DMF) filings, and the inspection history are not publicly disclosed.

2WHO & EU GMP

Eugia SEZ Private Limited's manufacturing facility has been prequalified by the World Health Organization (WHO), indicating compliance with international standards of quality, safety, and efficacy. Additionally, the facility adheres to European Union Good Manufacturing Practices (EU GMP), ensuring that its products meet the stringent requirements of the European market. These certifications underscore the company's commitment to maintaining high-quality manufacturing standards.

3CDSCO & Indian Regulatory

MS Eugia SEZ Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Eugia SEZ Private Limited operates in a competitive landscape, with several key players in the pharmaceutical manufacturing sector. While specific market share data is not publicly disclosed, the company's focus on high-quality finished pharmaceutical formulations positions it favorably in the market. Eugia's adherence to international standards, such as WHO prequalification and EU GMP certification, enhances its competitiveness. The company's strategic focus on both developed and emerging markets further strengthens its position against competitors.

2Key Differentiators

Eugia SEZ Private Limited's key differentiators include its WHO prequalification and EU GMP certification, which attest to the high quality of its manufacturing processes. The company's strategic location within the SEZ provides tax incentives and streamlined export procedures, enhancing its operational efficiency. Additionally, Eugia's diversified export portfolio across various regions mitigates concentration risk and leverages growth opportunities in different markets.

3Strategic Position

Buyer Due Diligence Brief — Evaluating MS Eugia SEZ Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Eugia SEZ Private Limited has demonstrated a strong track record in pharmaceutical manufacturing, with a focus on high-quality finished formulations. The company's export volume and consistency are supported by its WHO prequalification and EU GMP certification, which facilitate access to various international markets. Eugia's adherence to regulatory standards and its strategic location within the SEZ contribute to its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Eugia SEZ Private Limited as a supplier:

FDA Facility Registration: Confirm the facility's registration status with the U.S. FDA to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify the WHO prequalification status to ensure the facility meets international manufacturing standards.

EU GMP Certification: Check for EU GMP certification to confirm adherence to European manufacturing practices.

Frequently Asked Questions — MS Eugia SEZ Private Limited

How many pharmaceutical products does MS Eugia SEZ Private Limited export from India?

MS Eugia SEZ Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Piperacillin ($1.6M), Ampicillin ($650.0K). Total export value is $2.2M.

What is MS Eugia SEZ Private Limited's total pharmaceutical export value?

MS Eugia SEZ Private Limited's total pharmaceutical export value is $2.2M, based on 44 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does MS Eugia SEZ Private Limited cover?

MS Eugia SEZ Private Limited exports across 2 therapeutic categories. The largest are Advanced Antibiotics (70.5%, 1 products), Antibiotics (29.5%, 1 products).

Get Full MS Eugia SEZ Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.